KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Buildings (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Buildings for 17 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • Quarterly Buildings rose 7.99% to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, up 7.99% year-over-year, with the annual reading at $4.5 billion for FY2025, 7.99% up from the prior year.
  • Buildings hit $4.5 billion in Q4 2025 for Abbott Laboratories, up from $4.2 billion in the prior quarter.
  • In the past five years, Buildings ranged from a high of $4.5 billion in Q4 2025 to a low of $4.0 billion in Q4 2021.
  • Historically, Buildings has averaged $4.2 billion across 5 years, with a median of $4.2 billion in 2023.
  • Biggest five-year swings in Buildings: decreased 0.17% in 2021 and later increased 7.99% in 2025.
  • Year by year, Buildings stood at $4.0 billion in 2021, then grew by 1.15% to $4.1 billion in 2022, then grew by 2.66% to $4.2 billion in 2023, then increased by 1.11% to $4.2 billion in 2024, then grew by 7.99% to $4.5 billion in 2025.
  • Business Quant data shows Buildings for ABT at $4.5 billion in Q4 2025, $4.2 billion in Q4 2024, and $4.2 billion in Q4 2023.